OMER – Omeros Corporation
Omeros CorporationOMER
$7.38Name : Omeros Corporation
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $428,511,584.00
EPSttm : -3.14
Omeros Corporation
$7.38
0.27%$0.02Float Short %
17.13
Margin Of Safety %
Put/Call OI Ratio
0.49
EPS Next Q Diff
EPS Last/This Y
-1.27
EPS This/Next Y
1.32
Price
7.36
Target Price
32.33
Analyst Recom
1.8
Performance Q
-25.51
Relative Volume
2.13
Beta
2.41
Ticker: OMER
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-05 | OMER | 8.39 | 0.48 | 0.07 | 24579 |
| 2025-03-06 | OMER | 7.47 | 0.48 | 0.43 | 24599 |
| 2025-03-07 | OMER | 7.65 | 0.48 | 0.55 | 24938 |
| 2025-03-10 | OMER | 7.04 | 0.48 | 0.59 | 25122 |
| 2025-03-11 | OMER | 7.39 | 0.48 | 999.99 | 25702 |
| 2025-03-12 | OMER | 8.01 | 0.48 | 0.03 | 25695 |
| 2025-03-13 | OMER | 7.87 | 0.48 | 0.75 | 25801 |
| 2025-03-14 | OMER | 8.44 | 0.48 | 0.27 | 26036 |
| 2025-03-17 | OMER | 8.53 | 0.48 | 0.08 | 26128 |
| 2025-03-18 | OMER | 8.93 | 0.46 | 0.12 | 26814 |
| 2025-03-19 | OMER | 8.99 | 0.46 | 0.19 | 27095 |
| 2025-03-20 | OMER | 9.1 | 0.46 | 1.76 | 27226 |
| 2025-03-21 | OMER | 9.1 | 0.46 | 0.29 | 27284 |
| 2025-03-24 | OMER | 9.02 | 0.50 | 0.53 | 21990 |
| 2025-03-25 | OMER | 9.17 | 0.50 | 0.34 | 22170 |
| 2025-03-26 | OMER | 8.5 | 0.50 | 0.71 | 22734 |
| 2025-03-27 | OMER | 8.93 | 0.52 | 0.17 | 23925 |
| 2025-03-28 | OMER | 8.47 | 0.51 | 0.55 | 24470 |
| 2025-03-31 | OMER | 8.23 | 0.50 | 0.95 | 25075 |
| 2025-04-01 | OMER | 7.91 | 0.51 | 0.11 | 26504 |
| 2025-04-02 | OMER | 7.99 | 0.48 | 0.59 | 28008 |
| 2025-04-03 | OMER | 7.35 | 0.49 | 0.06 | 28113 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-05 | OMER | 8.37 | -2.2 | - | -3.15 |
| 2025-03-06 | OMER | 7.47 | -2.2 | - | -3.15 |
| 2025-03-07 | OMER | 7.65 | -2.2 | - | -3.15 |
| 2025-03-10 | OMER | 7.04 | -2.2 | - | -3.15 |
| 2025-03-11 | OMER | 7.40 | -2.2 | - | -3.15 |
| 2025-03-12 | OMER | 8.01 | -2.2 | - | -3.15 |
| 2025-03-13 | OMER | 7.86 | -2.2 | - | -3.15 |
| 2025-03-14 | OMER | 8.42 | -2.2 | - | -3.15 |
| 2025-03-17 | OMER | 8.52 | -2.2 | - | -3.15 |
| 2025-03-18 | OMER | 8.92 | -2.2 | - | -3.15 |
| 2025-03-19 | OMER | 8.98 | -2.2 | - | -3.15 |
| 2025-03-20 | OMER | 9.10 | -2.2 | - | -3.15 |
| 2025-03-21 | OMER | 9.09 | -2.2 | - | -3.15 |
| 2025-03-24 | OMER | 9.02 | -2.2 | - | -3.15 |
| 2025-03-25 | OMER | 9.16 | -2.2 | - | -3.15 |
| 2025-03-26 | OMER | 8.52 | -2.2 | - | -3.15 |
| 2025-03-27 | OMER | 8.93 | -2.2 | - | -3.15 |
| 2025-03-28 | OMER | 8.47 | -2.2 | - | -3.15 |
| 2025-03-31 | OMER | 8.22 | -2.2 | - | -3.15 |
| 2025-04-01 | OMER | 7.91 | -2.2 | - | -3.15 |
| 2025-04-02 | OMER | 8.01 | -2.2 | - | -3.15 |
| 2025-04-03 | OMER | 7.36 | -2.2 | - | -3.15 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-05 | OMER | 0.00 | 5.42 | 17.07 |
| 2025-03-06 | OMER | 0.00 | 5.42 | 17.07 |
| 2025-03-07 | OMER | 0.00 | 5.42 | 17.07 |
| 2025-03-10 | OMER | 0.00 | 5.97 | 17.07 |
| 2025-03-11 | OMER | 0.00 | 5.97 | 17.07 |
| 2025-03-12 | OMER | 0.00 | 5.97 | 16.67 |
| 2025-03-13 | OMER | 0.00 | 5.97 | 16.67 |
| 2025-03-14 | OMER | 0.00 | 5.97 | 16.67 |
| 2025-03-17 | OMER | 0.00 | 6.05 | 16.67 |
| 2025-03-18 | OMER | 0.00 | 6.05 | 16.67 |
| 2025-03-19 | OMER | 0.00 | 6.05 | 16.67 |
| 2025-03-20 | OMER | 0.00 | 6.05 | 16.67 |
| 2025-03-21 | OMER | 0.00 | 6.05 | 16.67 |
| 2025-03-24 | OMER | 0.00 | 6.05 | 16.67 |
| 2025-03-25 | OMER | 0.00 | 6.05 | 16.67 |
| 2025-03-26 | OMER | 0.00 | 6.05 | 17.16 |
| 2025-03-27 | OMER | 0.00 | 6.05 | 17.16 |
| 2025-03-28 | OMER | 0.00 | 6.05 | 17.16 |
| 2025-03-31 | OMER | 0.00 | 6.04 | 17.16 |
| 2025-04-01 | OMER | 0.00 | 6.04 | 17.16 |
| 2025-04-02 | OMER | 0.00 | 6.04 | 17.16 |
| 2025-04-03 | OMER | 0.00 | 6.04 | 17.13 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.82
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
6.04
Beta
2.41
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
3
Growth Score
21
Sentiment Score
13
Actual DrawDown %
71.1
Max Drawdown 5-Year %
-95.4
Target Price
32.33
P/E
Forward P/E
PEG
P/S
P/B
P/Free Cash Flow
EPS
-2.7
Average EPS Est. Cur. Y
-3.15
EPS Next Y. (Est.)
-1.83
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
2.13
Return on Equity vs Sector %
67.4
Return on Equity vs Industry %
80.3
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
Omeros CorporationSector: Healthcare
Industry: Biotechnology
Employees: 202
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
stock quote shares OMER – Omeros Corporation Stock Price stock today
news today OMER – Omeros Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch OMER – Omeros Corporation yahoo finance google finance
stock history OMER – Omeros Corporation invest stock market
stock prices OMER premarket after hours
ticker OMER fair value insiders trading